Pioglitazone-where do we stand in india?

Journal of Association of Physicians of India

Volumn 60, Issue 1, 2012, Pages 68-70

  Mohan, Viswanathan ^a   Bedi, Sharad ^a   Unnikrishnan, Ranjit ^a   Sahay, Binode Kumar ^b   Joshi, Shashank ^c   Misra, Anoop ^d  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

^b Sahay's Diabetic Clinic and Research Centre   (India)

^c LILAVATI HOSPITAL AND RESEARCH CENTRE   (India)

^d FORTIS HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; PIOGLITAZONE;

ARTICLE; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG TOXICITY; HUMAN; INDIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; TIME;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; HUMANS; INDIA; INSULIN RESISTANCE; RISK ASSESSMENT; THIAZOLIDINEDIONES; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84855541152     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bailey CJ, Krentz AJ. Textbook of Diabetes. 4th Edition. Wiley Blackwell Publication; Chapter 29. Oral Antidiabetic Agents 2010;452-77.
2. http://rezulin-lawsuit-lawyer.com/index.html. Accessed on June 19, 2007.
3. www.fda.gov/ohrms/dockets/AC/04/transcripts/2004-4062T1.pdf. Accessed on 18 June 2011.
4. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8.
5. Levy D, Viberti G, Kahn S, et al. A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2002;25:1737-1743.
6. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Lancet 2006;368:1096-105.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
8. http://pharmacovigilanceforum.com/pharmacovigilance-news-andevents/rosiglitazone-banned-in-india/. Assessed on 24 July 2011.
9. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events). Lancet 2005;366:1279-89.
10. Nissen SE, Nicholls SJ, Wolski K, et al. PERISCOPE Investigators. Comparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. The PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73.
11. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes. A randomized trial. JAMA 2006;296:2572-81.
12. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6.
13. Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care 2007;30:384-8.
14. DeFronzo RA, Tripathy D, Schwenke DC, et al; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011;364:1104-15.
15. Suzuki S, Arnold LL, Pennington KL, et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010;113:349-357.
16. Panigrahy D, Huang S, Kieran MW, Kaipainen A. PPARγ as a therapeutic target for tumour angiogenesis and metastasis. Cancer Bol Ther 2005;4:687-693.
17. Clay CE, Namen AM, Atsumi G et al. Magnitude of peroxisome proliferator-activated receptor gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med 2001;49:413-420.
18. Scher HI, Motzer RJ. Harrison's principles of Internal Medicine. 17th Edition. McGraw Hills Publications, Chapter 29, Bladder and renal cell carcinomas. 2008;589-93.
19. Mostofi FK, Davis CJ, Sesterhenn IA: Pathology of tumors of the urinary tract. In: Skinner DG, Lieskovsky G, eds.: Diagnosis and management of genitourinary cancer. Philadelphia, WB Saunders, 1988;83-117.
20. Wilson TG, Pritchett TR, Lieskovsky G, et al.: Primary adenocarcinoma of bladder. Urology 1991;38:223-6.
21. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. Diabetes Care 2011;34:1369-1371.
22. Lewis J, Quesenberry Jr C, Ferrara A, Vaughn D, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone. Diabetes Care 2011;34:91-92.
23. http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm. Accessed on 16 June, 2011.
24. http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2011/07/WC500109179.pdf. Assessed on 24 July 2011.
25. Mohan V, Sharp PS, Cloke HR, Burrin JM, Schemer B, Kohner EM. Serum immunoreactive insulin responses to a glucose load in Asian Indian and European Type 2 (non-insulin dependent) diabetic patients and control subjects. Diabetologia 1986;29:235-237.
26. Sharp PS, Mohan V, Levy JC, Mather HM and Kohner EM. Insulin resistance in patients of Asian Indian and European origin with non-insulin dependent diabetes. Horm Metab Res 1987;19:84-85.